Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors

Genes Chromosomes and Cancer

Volumn 51, Issue 12, 2012, Pages 1133-1143

  Poeta, Maria Luana ^a   Massi, Emanuela ^a,b   Parrella, Paola ^c   Pellegrini, Pasquale ^b,d   De Robertis, Mariangela ^b   Copetti, Massimiliano ^c   Rabitti, Carla ^e   Perrone, Giuseppe ^e   Muda, Andrea Onetti ^e   Molinari, Francesca ^f   Zanellato, Elena ^f   Crippa, Stefano ^f   Caputo, Damiano ^e   Caricato, Marco ^e   Frattini, Milo ^f   Coppola, Roberto ^e   Fazio, Vito Michele ^b,c  

^a UNIVERSITY OF BARI   (Italy)

^b Section of Molecular Medicine and Biotechnology   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,4 GALACTOSYLTRANSFERASE 1; BIOLOGICAL MARKER; GALACTOSYLTRANSFERASE; HISTONE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B4GALT1 GENE; BRAF ONCOGENE; CANCER INVASION; CANCER PATIENT; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR GENE;

AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GALACTOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84867233080     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21998     Document Type: Article

References (59)

1. Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM. 2008. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 18: 1105-1118.
2. An HJ, Kronewitter SR, de Leoz ML, Lebrilla C. 2009. Glycomics and disease markers. Curr Opin Chem Biol 13: 601-607.
3. Asano M, Furukawa K, Kido M, Matsumoto S, Umesaki Y, Kochibe N, Iwakura Y. 1997. Growth retardation and early death of b1, 4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells. EMBO J 16: 1850-1857.
4. Ballestar E, Esteller M. 2008. Epigenetic gene regulation in cancer. Adv Genet 61: 247-267.
5. Center MM, Jemal A, Smith RA, Ward E. 2009. Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378.
6. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD. 2005. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97: 1124-1132.
7. Cho MH, Lee YM, Kim JS, Kim HS, Lee KH, Juhng SW, Lee JH. 2010. Aberrant promoter methylation of the vimentin gene in colorectal cancer associated with the adenoma-carcinoma sequence. Korean J Pathol 2: 179-186.
8. Corvalan AH, Maturana MJ. 2010. Recent patents of DNA methylation biomarkers in gastrointestinal oncology. Recent Pat DNA Gene Seq 4: 202-209.
9. de Vos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C. 2009. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55: 1337-1346.
10. Durr ML, Mydlarz WK, Shao C, Zahurak ML, Chuang AY, Hoque MO, Westra WH, Liegeois NJ, Califano JA, Sidransky D, Ha PK. 2010. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One 5: e10828.
11. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. 2010. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573.
12. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
13. Feinberg AP, Ohlsson R, Henikoff S. 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
14. Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, Costa A, Daidone MG, Leo E, Pilotti S, Bertario L, Pierotti MA. 2004. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 10: 4015-4021.
15. Furukawa K, Sato T. 1999. Beta-1, 4-galactosylation of N-glycans is a complex process. Biochim Biophys Acta 1473: 54-66.
16. Grady WM, Markowitz SD. 2002. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3: 101-128.
17. Hakomori S. 1985. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perspectives. Cancer Res 45: 2405-2414.
18. Hakomori S. 2002. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA 99: 10231-10233.
19. Hart GW, Copeland RJ. 2010. Glycomics hits the big time. Cell 143: 672-676.
20. Herceg Z, Hainaut P. 2007. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 1: 26-41.
21. Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
22. Herranz M, Esteller M. 2007. DNA methylation and histone modifications in patients with cancer: Potential prognostic and therapeutic targets. Methods Mol Biol 361: 25-62.
23. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D. 2006a. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98: 996-1004.
24. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D. 2006b. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24: 4262-4269.
25. Hoque MO, Kim Ms, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, Schuuring E, Begum S, Rosenbaum E, Ongenaert M, Yamashita K, Califano J, Westra W, van der Zee AG, Van Criekinge W, Sidransky D. 2008. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 68: 2661-2670.
26. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
27. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61: 69-90.
28. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128: 683-692.
29. Kann L, Han J, Ahlquist D, Levin T, Rex D, Whitney D, Markowitz S, Shuber A. 2006. Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia. Clin Chem 12: 2299-2302.
30. Kannagi R, Yin J, Miyazaki K, Izawa M. 2008. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim Biophys Acta 1780: 525-531.
31. Kannagi R, Sakuma K, Miyazaki K, Lim KT, Yusa A, Yin J, Izawa M. 2010. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. Cancer Sci 101: 586-593.
32. Kawamura YI, Toyota M, Kawashima R, Hagiwara T, Suzuki H, Imai K, Shinomura Y, Tokino T, Kannagi R, Dohi T. 2008. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 135: 142-151.
33. Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste Js, Park HL, Chae YK, Yamashita K, Liu J, Ostrow KL, Ling S, Guerrero-Preston R, Demokan S, Yalniz Z, Dalay N, Meijer GA, Van Criekinge W, Sidransky D. 2009. Promoter DNA methylation of oncostatin m receport-beta as novel diagnostic and therapeutic marker in colon cancer. PLoS One 4: e6555.
34. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. 2008. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58: 130-160.
35. Li Z, Zong H, Kong X, Zhang S, Wang H, Sun Q, Gu J. 2006. Cell surface beta 1, 4-galactosyltransferase 1 promotes apoptosis by inhibiting epidermal growth factor receptor pathway. Mol Cell Biochem 291: 69-76.
36. Lind GE, Danielsen SA, Ahlquist T, Merok MA, Andresen K, Skotheim RI, Hektoen M, Rognum TO, Meling GI, Hoff G, Bretthauer M, Thiis-Evensen E, Nesbakken A, Lothe RA. 2011. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 10: 85.
37. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO. 2006. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327.
38. Mathews LA, Crea F, Farrar WL. 2009. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 78: 1-17.
39. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M. 2011. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17: 4901-4914.
40. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W, Sidransky D. 2010. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 6: 3463-3472.
41. Parrella P, la Torre A, Copetti M, Valori VM, Barbano R, Notarangelo A, Bisceglia M, Gallo AP, Balsamo T, Poeta ML, Carella M, Catapano D, Parisi S, Dallapiccola B, Maiello E, D'Angelo V, Fazio VM. 2009. High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. J Biomed Biotechnol 2009: 531692.
42. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. 2001. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
43. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. 2011. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 29: 2675-2682.
44. Rennert G. 2009. Are we getting closer to molecular population screening for colorectal cancer? J Natl Cancer Inst 101: 902-903.
45. Rodríguez-Paredes M, Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
46. Satomaa T, Heiskanen A, Leonardsson I, Angström J, Olonen A, Blomqvist M, Salovuori N, Haglund C, Teneberg S, Natunen J, Carpén O, Saarinen J. 2009. Analysis of the human cancer glycome identifies a novel group of tumor-associated N-acetylglucosamine glycan antigens. Cancer Res 69: 5811-5819.
47. Schmid G. 2010. The use of molecular markers in the diagnosis of colorectal cancer screening. Dig Dis 28: 625-628.
48. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. 2009. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29: 3759-3768.
49. Smith RA, Cokkinides V, Eyre HJ. 2006. American Cancer Society for the guidelines early detection of cancer, 2006. CA Cancer J Clin 56: 11-25.
50. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. 2011. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 61: 8-30.
51. Tsai HC, Baylin SB. 2011. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 21: 502-517.
52. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. 2011. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29: 1382-1391.
53. Verma M, Manne U. 2006. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol 60: 9-18.
54. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. 2008. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 149: 638-658.
55. Yamada Y, Watanabe A. 2010. Epigenetic codes in stem cells and cancer stem cells. Adv Genet 70: 177-199.
56. Yusa A, Miyazaki K, Kimura N, Izawa M, Kannagi R. 2009. Epigenetic silencing of sulfate transporter DTDST in colon cancer cells leads to decreased sulfated glycan expression. Proceedings for 68th Annual Meeting of the Japanese Cancer Association, Tokyo: Japanese Cancer Association 41.
57. Zhu X, Chen S, Yin X, Shen A, Ji S, Shen Z, Gu J. 2003. Constitutively active PKB/Akt inhibited apoptosis and down-regulated beta 1, 4-galactosyltransferase 1 in hepatocarcinoma cells. Biochem Biophys Res Commun 309: 279-285.
58. Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A, Frattini M, Terracciano L, Heinimann K, Lugli A. 2010. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer 127: 2569-2575.
59. Zou H, Harrington JJ, Shire Am, Rego RL, Wang L, Campbell ME, Oberg AL, Ahlquist DA. 2007. Highly methylated genes in colorectal neoplasia: Implications for screening. Cancer Epidemiol Biomarkers Prev 12: 2686-2696.